Ergebnis der Suchanfrage nach Celle

Technische Universität München

Multi-purpose mucus - What mucins can do in medicine

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE What mucins can do in medicine Multi-purpose mucus They are in our eyes, on our tongues, and in our stomachs: Protective layers of mucus, a slime consisting primarily of mucins. These are molecules which bind water to form a natural lubricant. Researchers at the Technical University of Munich (TUM) use them to develop coatings for contact lenses and intubation tubes, healing ...

GEA Group Aktiengesellschaft

3

GEA begins construction of technology center for alternative proteins in the USA

Medison Pharma; Alnylam Pharmaceuticals

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...

Helmholtz Zentrum München

Advanced Brain Science Without Coding Expertise

Fraunhofer-Institut für Produktionstechnologie IPT

Hydrogen technologies at the Hannover Messe 2024: Fraunhofer IPT presents system designs for the production of bipolar plates, MEAs and pressure tanks

CUSTOMCELLS®

CustomCells strengthens its commitment in eAviation

Norgine B.V.

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Amsterdam (ots/PRNewswire) - Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine's efforts to ...

Helmholtz Zentrum München

Asthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease

Asthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease Scientists have reached a milestone in the research of childhood asthma. For the first time, they have clarified how a certain genetic defect in children initially leads to frequent infections and later to asthma. The study, published in the American Journal of Respiratory and ...

Technische Universität München

Boron deficiency: oilseed rape reacts as with infection and pest infestation | Genetic mechanisms uncovered

TECHNICAL UNIVERSITY OF MUNICH PRESS RELEASE Genetic mechanisms uncovered Boron deficiency: oilseed rape reacts as with infection and pest infestation - Oilseed rape reacts to boron deficiency during flowering in a similar way as to pests and infections - Boron deficiency could become an increasing problem due to ...

Festo SE & Co. KG

You are cordially invited to Festo's press meeting with C. Gerhardt at Analytica

Helmholtz Zentrum München

Scientists Reveal Adipocyte's Metabolic Role and Identify Treatment Targets

ARTCLINE GmbH

ARTCLINE successfully completes capital increases of EUR 4.4 million

Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...

GEA Group Aktiengesellschaft

4

Technological milestone in the new food industry: GEA presents perfusion as key process at Anuga FoodTec

Norgine

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...

CUSTOMCELLS®

CustomCells founds U.S. subsidiary with Detroit site

GEA Group Aktiengesellschaft

Invitation to press briefing at Anuga FoodTec 2024: Discover the Future of New Food Production

GEA Group Aktiengesellschaft

Invitation to press briefing at Anuga FoodTec 2024: Discover the Future of New Food Production

WiN Emscher-Lippe

9

Football fans from Europe visit the champion of structural change in Gelsenkirchen

RHEACELL GmbH und Co. KG

Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘

Helmholtz Zentrum München

Rising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target

Aston Martin Lagonda of Europe GmbH

10

New Aston Martin Vantage GT4 completes top-flight line-up of production-based GT racers

GEA Group Aktiengesellschaft

4

GEA at the Anuga FoodTec trade show: Sustainability innovations bolster food industry resilience

Helmholtz Zentrum München

Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial

Helmholtz Zentrum München

What Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications

Acousia Therapeutics GmbH

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...

GEA Group Aktiengesellschaft

3

GEA invests EUR 18 million in technology center for alternative proteins in the USA

Aston Martin Lagonda of Europe GmbH

10

STATE-OF-THE-ART ASTON MARTIN VANTAGE GT3 SPEARHEADS NEW ERA IN TOP-FLIGHT GT RACING

Polaroid Therapuetics

Polaroid Therapeutics completes pre-clinical milestones in the development of superior antimicrobial technology for acute and chronic wounds

Bern, Switzerland (ots/PRNewswire) - - Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats - The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and ...

Deutsche Post DHL Group

2

PM: DHL Group mit Wasserstoff-LKWs im Rheinland unterwegs / PR: DHL Group deploying hydrogen trucks in Germany

Sysmex Europe SE

Strengthening the Direct Sales and Service System for Business Expansion in Italy